Claudin 18 (43–14A clone) expression in pancreatic ductal adenocarcinoma: Assessment of a potential clinical biomarker for zolbetuximab therapyRiley J. Arseneau, Thomas Arnason, Emma Kempster et al.|Translational Oncology|2025Cited by 11
Peri-tumoural lymphocyte neighbourhoods predict longer survival in pancreatic ductal adenocarcinomaRiley J. Arseneau, Jeanette E. Boudreau, Ravi Ramjeesingh et al.|Frontiers in Immunology|2025Cited by 3
Glypican-3 and Cytokeratin-19 Expression in Pancreatic Cancer in a Canadian PopulationCarley Bekkers, Thomas Arnason, Ravi Ramjeesingh|Journal of Clinical Medicine|2024Cited by 1
Longitudinal rotating pathology elective: Reflections on a pilot project in pathology at DalhousieAleksandra Kajetanowicz, Thomas Arnason, Patrick L. Holland et al.|Dalhousie Medical Journal|2020Cited by 0
Abstract B028: Claudin-18 expression (using the 43-14A antibody kit) in pancreatic ductal adenocarcinoma: Assessment of a potential clinical biomarker for immunotherapy with zolbetuximabRiley J. Arseneau, Thomas Arnason, Carley Bekkers et al.|Cancer Immunology Research|2024Cited by 0